A Machine Learning Model for Discovery of Protein Isoforms as Biomarkers by Alshehri, Manal
University of Windsor 
Scholarship at UWindsor 
Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 
2016 
A Machine Learning Model for Discovery of Protein Isoforms as 
Biomarkers 
Manal Alshehri 
University of Windsor 
Follow this and additional works at: https://scholar.uwindsor.ca/etd 
Recommended Citation 
Alshehri, Manal, "A Machine Learning Model for Discovery of Protein Isoforms as Biomarkers" (2016). 
Electronic Theses and Dissertations. 5900. 
https://scholar.uwindsor.ca/etd/5900 
This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor 
students from 1954 forward. These documents are made available for personal study and research purposes only, 
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, 
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder 
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would 
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or 
thesis from this database. For additional inquiries, please contact the repository administrator via email 
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208. 
A Machine Learning Model for Discovery of
Protein Isoforms as Biomarkers
By
Manal Alshehri
A Thesis
Submitted to the Faculty of Graduate Studies
through the School of Computer Science
in Partial Fulfillment of the Requirements for
the Degree of Master of Science
at the University of Windsor
Windsor, Ontario, Canada
2016
©2016 Manal Alshehri
A Machine Learning Model for Discovery of Protein Isoforms as Biomarkers
by
Manal Alshehri
APPROVED BY:
E. Abdel-Raheem
Department of Electrical and Computer Engineering
A. Ngom
School of Computer Science
L. Rueda, Advisor
School of Computer Science
Nov 30, 2016
DECLARATION OF ORIGINALITY
I hereby certify that I am the sole author of this thesis and that no part of this thesis has
been published or submitted for publication. I certify that, to the best of my knowledge, my
thesis does not infringe upon anyone’s copyright nor violate any proprietary rights and that
any ideas, techniques, quotations, or any other material from the work of other people in-
cluded in my thesis, published or otherwise, are fully acknowledged in accordance with the
standard referencing practices. Furthermore, to the extent that I have included copyrighted
material that surpasses the bounds of fair dealing within the meaning of the Canada Copy-
right Act, I certify that I have obtained a written permission from the copyright owner(s) to
include such material(s) in my thesis and have included copies of such copyright clearances
to my appendix. I declare that this is a true copy of my thesis, including any final revisions,
as approved by my thesis committee and the Graduate Studies office, and that this thesis
has not been submitted for a higher degree to any other University or Institution.
III
ABSTRACT
Prostate cancer is the most common cancer in men. One in eight Canadian men will
be diagnosed with prostate cancer in their lifetime. The accurate detection of the disease’s
subtypes is critical for providing adequate therapy; hence, it is critical for increasing both
survival rates and quality of life. Next generation sequencing can be beneficial when study-
ing cancer. This technology generates a large amount of data that can be used to extract
information about biomarkers.
This thesis proposes a model that discovers protein isoforms for different stages of
prostate cancer progression. A tool has been developed that utilizes RNA-Seq data to infer
open reading frames (ORFs) corresponding to transcripts. These ORFs are used as features
for classificatio. A quantification measurement, Adaptive Fragments Per Kilobase of tran-
script per Million mapped reads (AFPKM), is proposed to compute the expression level
for ORFs. The new measurement considers the actual length of the ORF and the length of
the transcript. Using these ORFs and the new expression measure, several classifiers were
built using different machine learning techniques. That enabled the identification of some
protein isoforms related to prostate cancer progression. The biomarkers have had a great
impact on the discrimination of prostate cancer stages and are worth further investigation.
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CHAPTER 1
Introduction
Deoxyribonucleic acid (DNA) is a two strand genetic material that contains all the in-
formation that is in living organisms. The information is stored as genetic codes using
adenine (A), guanine (G), cytosine (C), and thymine (T). Ribonucleic acid (RNA) consists
of the same nucleotides except using uracil (U) instead of thymine (T). The central dogma
of molecular biology indicates that the coded genetic information stored in the DNA is
transcribed into messenger RNA (mRNA) and then translated to form proteins. Protein
molecules are responsible for most of the functions necessary in organisms’ lives. Protein
synthesis consists of several steps during which transcripts are transformed into amino acid
chains. Almost all mRNA molecules undergo alternative splicing during or after transcrip-
tion. Alternative splicing is an important event in Eukaryotic in which the segments that
code for proteins (exons) are kept, and those that do not code for proteins (introns) are
removed. Different transcripts are the result of the different inclusion of exons. Regard-
ing post-transcriptional events, alternative splicing is the most important process due to its
impact on 95% of mammalian genes [53]. Formation of polypeptide chain occurs through
the translation of the actual open reading frame (ORF). ORF is a continuous sequence of
codons, and it begins with a start codon and ends with one of the stop codons. Finding
ORFs that correspond to a given mRNA transcript is a significant step in reconstructing
protein isoforms, which is vital for a better understanding of RNA alternative splicing and
its effects on diseases like cancer.
1
1.1 Transcription
The central dogma of molecular biology refers to transforming the genetic information
coded in DNA into proteins through two steps: transcription and translation. In transcrip-
tion, the first step of gene’s expression, a specific segment of a DNA strand is copied into
mRNA by the enzyme called RNA polymerase. Each mRNA strand holds the code for
the synthesis of a particular protein (or a small number of proteins). Transcription uses
complementary language, which means utilizing one strand of DNA as a template to pro-
duce a copy of the second strand, called a coding strand. A major characteristic of RNA
is that it includes the nucleotide uracil (U) instead of the nucleotide thymine (T) in a DNA
complement.
Transcription is divided into initiation, elongation, and termination. In the initiation
step, RNA polymerase, along with some general transcription factors, binds to promoter
DNA. The attached complex unwinds the two strands of the DNA helix to form a transcrip-
tion bubble. RNA polymerase and the general transcription factors select a transcription
start site in the transcription bubble. In the second step, elongation, RNA polymerase reads
the nucleotides in the DNA from the 3’ end to the 5’ end (3’→ 5’). During RNA poly-
merase traveling, the complementary RNA is created in the opposite direction (5’→ 3’) by
matching the sequence of the coding strand with the exception of substituting Uracil (U)
for Thymine (T). In the third step, transcription termination, the newly synthesized RNA
strand is cleaved, and RNA polymerase is released.
Transcription generates primary RNA (pre-mRNA) which undergoes some processes
to create mRNA. Post-transcriptional modification, co-transcriptional modification, is the
process of converting pre-mRNA into mRNA. The process is vital in Eukaryotes and con-
sists of three essential steps. The first step is processing the 5’ end; it takes place before
the completion of transcription as the pre-mRNA is being created. Capping involves the
addition of 7-methylguanosine to the 5’ end. The cap protects the 5’ end of the mRNA
transcript from degradation while transporting from the nucleus to the cytoplasm for trans-
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lation. The second step is processing the 3’ end through polyadenylation, which means
the addition of a 3’ poly-A tail. The poly-A tail is a stretch of several adenosine bases at
the end of the mRNA strand. The third step is alternative splicing, which is explained in
section 1.2.
1.2 Alternative Splicing
Eukaryotic genes consist of exons (ex-on indicates that they are expressed) and introns
(int-ron indicates that they are intervening sequences). Most of the human genes have
seven to eight exons and they spliced in three alternative forms. The average length of an
exon is 150 nucleotides long, and the average length of an intron is 3,000 nucleotides [54].
Splicing is the process by which introns in a pre-mRNA are removed, and the remaining
sequence (exons) concatenate together to form an mRNA sequence. Figure 1.2.1 depicts the
alternative splicing process. The figure demonstrates a pre-mRNA that undergo alternative
splicing to produce two different mRNAs, and hence two distinct proteins.
All introns in a pre-mRNA are precisely removed before the translation of the mRNA
sequence. If the splicing site errs by even a single nucleotide, the reading frame of the
joined exons will shift, and the resulting protein will be dysfunctional. Abnormal splicing
variants are thought to contribute to the development of cancer [16].
The splicing of pre-mRNAs in Eukaryotes occurs through spliceosomes, and it takes
place inside the nucleus either shortly after or during transcription. Spliceosomes are as-
sembled of five small nuclear ribonucleoproteins (snRNAs) and more than 100 other pro-
teins. The main role of spliceosomes in the splicing process is to catalyze RNA cleaving
and joining. In order to remove an intron in a given pre-mRNA, spliceosomes recognize
the 5’ and the 3’ splice site, and the branch site, which is in the middle of the intron. They
then join the splice sites and exclude the sequence, intron, between them.
There are different types of alternative splicing events; one of them is exon skipping,
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in which an exon (a cassette exon) is spliced out of the transcript along with flanking
introns. Another example is intron retention in which an intron remains in the mature
mRNA transcript.
Changes in the RNA expression machinery might lead to the mis-splicing of transcripts.
Even a single nucleotide alteration in a splice site can result in differences in the mRNA
produced from a mutant gene’s transcripts. A well-known example of a splicing-related
disease is cancer [53]. Irregularly spliced mRNAs are detected in a large proportion of
cancerous cells [44].
Alternative splicing increases the informational diversity and functional capacity of
a gene and provides an opportunity for gene regulation. In other words, it enables one
gene to produce a large variety of polypeptides (i.e., proteins) [3]. A single variation in
splicing may cause a given exon to be excluded from or included in a transcript, enabling
the production of a new protein isoform [54].
Figure 1.2.1: Schematic representation of alternative splicing.
1.3 Translation
Transcription happens exclusively in the nucleus, and the resulting mRNA exits the
nucleus to the cytoplasm through the nuclear pore complex. In the cytoplasm, the mRNA
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attaches to the ribosome (rRNA) and the translation process starts. Translation is a synthesis
of proteins, in which the nucleotide sequence of an mRNA is translated into an amino acid
sequence to yield a protein.
The protein synthesis requires a specialized machinery of high complexity, and it con-
sumes a large part of the energy produced in the cell. The translation process involves
a large number of chemical reactions and the participation of additional nucleic acid and
protein components. One of these elements, the ribosome, implements the basic machinery
for the translation process. The major role of the ribosome is coupling amino acids and an
mRNA strand based on the sequence specified by the mRNA. The amino acids are brought
to the ribosome by tRNA (transfer RNA) molecules.
The nucleotide sequence of the mRNA is composed of four different nucleotides (A,
U, G, and C) whereas a protein is composed of 20 different amino acids. To allow the four
nucleotides to specify 20 different amino acids, the nucleotide sequence is interpreted in
codons, namely groups of three nucleotides. These codons have corresponding anticodons
in the tRNA. Each anticodon is linked to one particular amino acid. Thus, each codon spec-
ifies one amino acid. The set of rules by which information is translated from mRNAs into
amino acids is demonstrated in the codon table, which is presented in Figure 1.3.1. In ad-
dition to the main components of the translational system mentioned above, the translation
process also involves many protein factors that facilitate the binding of mRNA and tRNA
to ribosome.
1.3.1 Translation Mechanism
There are three major classes of cellular RNAs involved in the translation process:
messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), and transfer RNAs (tRNAs). RNA
translation can be divided into three distinct steps: initiation, elongation, and termination
[54].
To initiate translation, a tRNA charged with methionine (tRNA+methionine) attaches
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Figure 1.3.1: Standard codon table for translating mRNA to polypeptide chain [35].
to a ribosome. The combination of the charged tRNA and the ribosome (a small subunit)
scans the mRNA from the 5’ end until it finds a start codon. When it finds the start sequence
AUG, a large subunit joins the small one to form a complete ribosome, and the protein
synthesis is initiated.
In the elongation phase, a new tRNA+amino acid enters the ribosome at the next codon
downstream of the start codon (AUG). If this tRNA’s anticodon matches the mRNA codon,
they both attach to each other, and the ribosome links the two amino acids together. If the
tRNA with the wrong anticodon enters the ribosome, it cannot base pair with the mRNA; it
is rejected. Next, the ribosome moves one triplet forward, and a new (tRNA+amino acid)
enters the ribosome; the procedure is then repeated.
Finally, translation termination occurs when the ribosome reaches one of three stop
codons (UAA, UAG, UGA); there are no corresponding tRNAs to stop codons. Instead, ter-
mination proteins bind to the ribosome and stimulate the release of the polypeptide chain
(the protein); the ribosome then dissociates from the mRNA. When the ribosome is re-
leased from the mRNA, its large and small subunit dissociate. The small subunit can then
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be loaded with a new tRNA+methionine and start translation once again. Some cells need
vast quantities of a particular protein; to meet this requirement they make many mRNA
copies of the corresponding gene and have many ribosomes working on each mRNA. Af-
ter translation, the produced protein will usually undergo further modifications before it
becomes fully active.
1.3.2 Open Reading Frame
An open reading frame (ORF) is the part of a reading frame that begins with a start codon
(AUG) and ends with a stop codon (either UAA, UAG, or UGA). ORFs have the potential to
be translated; hence, they have the potential to code for a protein or polypeptide chain. The
AUG codon indicates where translation starts and the methionine included in the created
polypeptide chain. However, stop codons do not appear inside the polypeptide chain. There
are no corresponding amino acids for stop codons, and when the translation process reaches
a stop codon, the polypeptide chain is released. Each ORF specifies a single protein that
starts and end at internal sites within the mRNA. The two ends of an ORF are different
from the ends of its mRNA [54].
Since the DNA code is translated into sets of three nucleotides (codons), a DNA strand
has three different reading frames. Each mRNA reading frame is a shift by one nucleotide.
The double helix of a DNA molecule has two strands; as a result, there are six possible
translations for the three frames in each strand. Figure 1.3.2 illustrates the six reading
frames of DNA. The upper DNA strand is called the first, positive, or (5’→ 3’) strand,
while the lower DNA strand is called the second, negative, or (3’→ 5’) strand. The first
reading frame in the positive strand is aligned with the first nucleotide. The second and
third reading frames start from the second and third nucleotides, respectively. Obtaining
the three reading frames for the negative strand follows the same principle as the positive
strand. For both strands, the direction for obtaining the reading frames is always (5’→ 3’).
Among all ORFs detected in the six reading frames, only one ORF is used when trans-
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Figure 1.3.2: Six reading frames in DNA [55]
lating a gene in Eukaryotes; it is the longest ORF [54].
1.3.3 Protein Isoforms
A protein isoform is any one of two or more similar proteins that have similar, not identical,
amino acid sequences and are encoded by mRNA transcripts from the same gene that has
been alternatively spliced. In addition, the term isoform is used to discibe highly similar
proteins that come from different genes. The creation of protein isoforms is an evolution-
ary event that allows for different diverse proteins to be created from a small amount of
genetic material. Alternative splicing is the main reason behind the formation of protein
isoforms. In alternative splicing, the exons of a gene may be included or excluded in pro-
cessed mRNA. Proteins translated from alternatively spliced mRNA contain differences in
their amino acid sequences; as a result they often differ in their biological functions [58],
[48]. Many studies investigated the relation between alternatively spliced mRNA tran-
scripts and unusual characteristics; however, it is much more complicated to explore the
existence of alternative variants and protein isoforms at the protein level [44]. Isoform can
also be defined as follows:
• Any of the proteins with the same function and a similar amino acid sequence, en-
coded by different genes or by RNA transcript [3].
• The protein products of different versions of messenger RNA created from the same
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gene by employing different promoters, which cause transcription to skip certain
exons. Since the promoters are tissue-specific, different tissues express different
protein products of the same gene [22].
The term isoform causes endless confusion; however, in this thesis the term isoform
refers to the various forms of a protein at the amino-acid level, regardless of their genetic
origin [13].
1.4 Prostate Cancer
Prostate Cancer is the most commonly diagnosed cancer among Canadian men [36].
Cancerous prostate cells have uncontrolled growth and division, and can invade other parts
of the body. Early prostate cancer does not usually cause any symptoms at all. The typical
method of screening prostate cancer is the prostate-specific antigen (PSA) test. A PSA is
a protein produced by the cells of the prostate gland. The PSA test measures the level of
PSAs in a man’s blood, and the test is reported as nanograms PSAs per milliliter (ng/mL)
of blood. If the PSA level is above the normal range (4.0 ng/mL), it is interpreted as a sign
of prostate cancer. After that, further tests such as digital rectal exam (DRE), a pathological
validation, and a biopsy will be done. Specialists try to accumulate as much information
as possible so that they can determine the exact stage of cancer and subsequently provide
the best treatment options. Staging is a way of classifying cancer based on the degree of
spreading of cancer in the body. According to the Canadian Cancer Society [6], prostate
cancer has four main stages.
• Stage 1, the tumor starts developing in the prostate tissue, but tumour involves half a
lobe or less.
• Stage 2, the tumor grows and may occupys more than half a lobe but is limited to the
prostate.
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• Stage 3, the tumor has spread beyond the prostatic capsule or into the bladder neck
or seminal vesicles.
• Stage 4, tumor has invaded other tissues and organs such as the rectum, pelvic wall,
lymph nodes, bladder.
1.5 RNA-Seq Technology
The transcriptome is the set of all RNA molecules, including mRNAs, non-coding RNAs,
and small RNAs present in a cell at a particular time. Understanding the transcriptome and
quantifying transcripts is vital for interpreting gene activity and expression in a specific cell
or tissue type, and hence understanding diseases and their developments [52]. RNA-Seq
refers to techniques used to determine the primary sequence and relative abundance of the
transcriptome within a biological sample. Several studies have uncovered critical informa-
tion using nucleotide resolution. For example, previous research estimated that roughly
60% of human genes are alternatively spliced [12], while next-generation sequencing data
estimates that approximately 95% of all human genes are alternatively spliced [32].
In recent years, RNA-Seq has become the preferred technique for transcriptome stud-
ies, including alternatively spliced transcripts and their corresponding protein isoforms
[15], [28], [45]. RNA-Seq has the power to provide precise information about alternative
transcripts or proteins and the mechanisms that contribute to their formations. RNA-Seq
technology has improved researchers’ understanding of gene regulations: transcription,
post-transcription, and translation; however, its analyses remain challenging.
Studying cancer at the nucleotide level can provide relevant information about the tu-
mor initiation mechanisms and progression; it consequently, benefits diagnosis, prognosis,
and treatment. Although several studies have concentrated on finding genes as biomark-
ers, they have not completely utilized the high-resolution feature that RNA-Seq technology
provides.
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1.6 Biomarkers
According to the Dictionary of Cancer Terms (NCI), a biomarker is biological molecule
found in blood, other bodily fluids, or tissues that is a sign of a normal or abnormal process
or a condition or disease [30]. There is a large variety of biomarkers, which can include
genes, nucleic acids, and proteins, among other categories. Biomarkers can be identified in
blood circulation or excretions such as the urine, and can thus be assessed non-surgically.
They can also be identified in tissues, which require imaging to be evaluated.
Genetic biomarkers can be inherited or somatic. Inherited biomarkers are detected as a
DNA sequence, and they are isolated from the blood. Somatic biomarkers are recognized as
mutations in DNA obtained from tumor tissue. Biomarkers can be used in various evalua-
tions, including investigating the risk of a particular disease, screening for primary cancers,
discriminating between benign and malignant tumors, distinguish one stage of cancer from
another, monitoring the status of a cancer, and assessing a cancer’s response to therapy.
The classic approach for detecting cancer biomarkers is finding biomarkers based on
tumor biology and surrounding environment. With the improved knowledge about cancer
and the emergence of new technologies, biomarker discovery is often performed using
techniques such as RNA-Seq that identify single or multiple biomarkers in a significantly
short amount of time.
The search for cancer biomarkers has been for years a hot topic of research. Although
many efforts are being devoted to the search for new cancer biomarkers, the discovery of
these molecules has been carried out at a slow pace [51].
Several studies have discovered biomarkers as genes for prostate cancer. For example,
Xu et al. [45] investigated five cancer samples using RNA-Seq technology. That study
founf 116 somatic mutations in 92 genes that are related to prostate cancer. Additionally,
Long et al. conducted another study on global transcriptome analysis [27]. They identified
16 genes associated with cancer in which five genes are related to prostate cancer.
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1.7 Problem and Motivation
As mentioned above, prostate cancer rates are highest among Canadian men [37]. An
appropriate diagnosis of the particular stage of prostate cancer in a patient is critical to
ensure the patient is provided the best suitable treatment and his survival rates is increased.
The typical approach for detecting or staging prostate cancer is studying PSA protein
levels. However, some studies show that testing PSA levels in the blood is not the ideal
marker for discovering or staging prostate cancer [31], since a proportion of men with
prostate cancer have PSA values lower than 4.0 ng/mL. Further, a test with PSA level
above 4.0 ng/mL does not always prove the existence of prostate cancer because it can
be related to other prostatic diseases [24]. Moreover, PSA levels decrease dramatically in
advanced stages of prostate cancer. Therefore, one of the most promising tools to improve
the use of PSA as a tumor marker is measuring the proportion of PSA’s different isoforms
[31].
However, in recent years researchers have worked on detecting genetic biomarkers for
different types of cancer, including prostate cancer. The focus has mainly been on the ge-
netic level to discover differentially expressed genes. However, studying the transcriptome
activity and investigating protein isoforms as biomarkers are more promising than finding
biomarkers at the gene level, due to the precise information that protein isoforms provide
about tumor condition and progression.
This thesis focuses on identifying a small subset of protein isoforms that can reliably
discriminate between stages of prostate cancer with a very high accuracy.
1.8 Contributions
This thesis integrates RNA-Seq data with machine learning techniques to predict
prostate cancer progression. First, a tool is developed to find the ORF in all six frames
corresponding to a given mRNA sequence and identifying the actual ORF from RNA-Seq
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data. The proposed model can find both known and novel protein isoforms corresponding
to a given mRNA using RNA-Seq data.
Second, a machine-learning approach is developed that uses protein isoforms as fea-
tures and differentiates between prostate cancer stages. The model delivers a handful of
relevant biomarkers that can be utilized at the protein level and can open new avenues
toward better understanding the progression of prostate cancer. Using identified protein
isoforms, prostate cancer stages were discriminated between with a very high accuracy.
This thesis consists of six chapters, starting with an introduction, which provides an
overview of the main topics. Machine learning techniques are presented in Chapter 2. The
literature review is included in Chapter 3. The thesis’s methods and results are discussed in
Chapters 4 and 5, respectively. Finally, Chapter 6 presents the thesis conclusions and the
future work derived from this thesis.
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CHAPTER 2
Machine Learning
Machine learning is a branch of the computer science field that combines pattern recog-
nition, artificial intelligence, and computational statistics. Machine learning involves the
implementation of computer algorithms that learn from data and make predictions instead
of depending on a static program.
Machine learning algorithms are categorized as supervised learning, unsupervised learn-
ing, and semi-supervised learning. Supervised learning algorithms construct a model from
sample inputs, or a training set, to make predictions for new samples, or a test set. A su-
pervised learning problem could be, for instance, cancer diagnosis in which the aim is to
categorize a patient (or sample) as malignant or benign. Unsupervised learning consists of a
set of inputs without any corresponding class value, in such a way that the algorithms forms
clusters or natural groupings of the samples based on observed patterns. Semi-supervised
learning labels some of the data, and a model makes use of both labeled and unlabeled data.
Feature selection and classification are two applications of machine learning, and they are
discussed next.
2.1 Feature Selection
Feature selection is the process of selecting a subset of relevant attributes to be used in
the classification model construction. Feature selection techniques are used to identify and
remove irrelevant and redundant attributes that do not improve the accuracy of a classifier
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or may, in fact, decrease the accuracy of the model. The primary goals of feature selection
are to speed up the classification process and to increase the classification efficiency as
much as possible.
The most common aspect of classifying biological data is the high-dimensional nature
of the task; an enormous number of features are used with a small group of samples. With
a wide range of features, the computational complexity of classification algorithms grows
exponentially with each increase in dimension. For this purpose, a subset of features is
chosen carefully by feature selection algorithms to build the classification model.
There are two categories of feature selection approaches: filter methods and wrapper
methods. Filter methods score and rank the features based on their quality; they are fast
because they evaluate each feature independently. Chi-squared [25] is an example of a
filter-based feature selection technique. The method evaluates the relevance of a feature by
calculating the chi-squared value; the higher the value of chi-squared, the more relevant the
feature is.
Wrapper methods are another way to select a subset of features. They automatically
determine the number of selected features. They find the best subset of attributes using
a predictive classifier to score feature subsets. Unlike filter approaches, wrapper methods
consider all relationships among features. They are computationally expensive because
they perform an exhaustive search to discover the best subset of features. An example of a
wrapper-based methods is the minimum redundancy maximum relevance (mRMR) method
[33]. The mRMR method selects features that yield the highest relevance with the target
class and are maximally dissimilar to each other. A classification algorithm is needed since
mRMR is a wrapper method.
The mRMR feature selection approach was used in this thesis to select the most infor-
mative features associated with prostate cancer progression.
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2.2 Classification
Classification is one of the primarily supervised learning applications in machine
learning. The objective of classification is to assign new instances to one of the known
categories, or classes, depending on training dataset that consists of samples with known
labels. Classification schemes aim to correctly classify samples such as biological data
with the best possible performance.
In this thesis, the input vectors, or features, are the ORFs that are generated by the
proposed method. Each patient sample has a corresponding class label that indicates the
stage of prostate cancer to which the sample belongs. Various algorithms designed for
classification problems such as Naive Bayes, support vector machine (SVM), random tree,
and random forest were used. The next section discusses some of these classifiers.
2.2.1 Support Vector Machine
The support vector machine (SVM) is a widely used classifier due to its generalization
power and its suitability for small training datasets along that have a large number of fea-
tures [11]. SVM is a supervised learning model that represents samples as points in space
and finds the separating hyperplane with the largest margin. The larger the margin, the
better the classifier is. The classifier’s numeric input vectors form an n-dimensional space,
and the hyperplane is a line that splits the input variable space.
There are two categories of SVM models related to data distribution: linear SVM and
non-linear SVM [8]. Figure 2.2.1 shows an example of linearly separable data. The figure
shows two separating hyperplanes, H1 and H2, that can be applied to given training sam-
ples. Although both hyperplanes separate the two classes linearly, the optimal hyperplane
is H1 because it separates the classes with the maximum distance. Support vectors are the
most difficult samples to be classified; they are used to determine the hyperplane’s position.
A linear kernel function is recommended when a linear separation of the data is straight-
16
forward; in other cases, the kernel trick is used. The kernel trick concentrates on mapping
the input samples onto a higher dimensional feature space. The SVM then tries to choose a
hyperplane that separates the classes as clearly as possible with the maximum width of the
margin; that case is known as the soft margin.
Different kernel functions need to be tested to obtain the best model in each case, as
they each use different algorithms and parameters. Both linear SVM and non-linear SVM
were examined. Different kernel functions such as polynomial and radial basis function
(RBF) were tested.
Figure 2.2.1: Separating hyperplane and margin for linearly separable classification prob-
lem, H1 is optimal hyperplane with maximum distance between classes.
2.2.2 Decision Tree
A decision tree is an effective classification method based on Quinlan’s algorithm [39].
It consists of a root node, internal nodes, and leaves. Each node indicates a test on a feature,
and each branch substitutes the result of the test. The final decision, or class label, is found
in the leaves for samples that verify all test paths from the root to the leaves.
Each decision tree is constructed throughout multiple steps using a set of learning sam-
ples. In each step, samples are divided into smaller groups based on particular criteria.
Some examples for the criteria used in tree design are minimum error rate, minimum or
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maximum path length, minimum number of nodes, and maximum information gain [41].
The node that provides the best value for the criteria among all nodes is the root node. New
samples are classified starting from the root, and they follow the branch direction based on
the test at each internal node until a leaf, or class label, is reached.
An example of a decision tree for playing tennis is shown in Figure 2.2.2. The figure
shows a decision tree that provides a decision on playing tennis based on three attributes:
outlook, humidity and wind speed. Outlook attribute has the highest value, and so it is used
as a decision attribute, or the root node. As shown in the figure, if the outlook is rainy
and very windy, the decision to play tennis is a No, while if the outlook is sunny and the
humidity is normal, the decision to play tennis is a Yes.
Figure 2.2.2: Decision tree for playing tennis based on outlook, humidity, and wind.
2.2.3 Random Forest
Random forest is a classification method based on constructing a forest of random
trees; each tree produces a vote in classifying. [20]. A random subset of the training data is
used to build each decision tree. After training the forest, new samples can be passed to the
forest to predict their classes. The larger the forest, the higher accuracy is gained without
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suffering from overfitting. There are two factors that affect random forest’s performance:
the correlation between trees and the accuracy of each tree. Increasing the number of
features used in each tree increases the tree’s performance as well as the correlation; hence,
increasing the number of features used in each tree increases the forest’s performance. The
classification of new samples in the random forest is based on voting. Each tree in the
forest votes to one of the classes; the class with the highest number of votes is assigned to
the new observation. Figure 2.2.3 shows an example of a random forest containing N trees.
For a new sample, X, each tree votes for one of the classes. The final class is determined
by the majority voting.
Figure 2.2.3: Random forest.
2.2.4 Naive Bayes
Naive Bayes is a classification algorithm that is based on Bayes’ theorem [40]. Clas-
sification using Naive Bayes depends on prior probability and likelihood. A classification
is produced by combining both sources of information: the prior probability and the like-
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lihood of forming a posterior probability using Bayes’ rule. This classifier assumes that
the presence of a feature in a class is independent from the presence of any other feature.
Making predictions involves calculating the probability that a given data instance belongs
to each class, and then selecting the class with the largest probability as the prediction.
2.3 Performance Evaluation
Performance measures are a way to evaluate a solution to a problem. They are the
measurements for predictions made by a trained model on a test dataset. Some concepts
related to performance evaluation are introduced below.
2.3.1 Confusion Matrix
Suppose that there are two classes: positive and negative. The confusion matrix of these
two classes is shown in Figure 2.3.1.
Figure 2.3.1: Confusion matrix corresponding to original samples and classified samples
for two classes.
• TP is the number of true positives or the number of samples that belong to the positive
class and have been classified as positive.
• TN is the number of true negatives or the number of samples that belong to the
negative class and have been classified as negative.
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• FP is the number of false positives or the number of samples that belong to the
negative class, but have been incorrectly classified as positive.
• FN is the number of false negatives or the number of samples that belong to the
positive class, but have been incorrectly classified as negative.
Different performance measures can be calculated using the confusion matrix as fol-
lows:
Accuracy =
TP + TN
TP + FP + TN + FN
(2.3.1)
Recall(Sensitivity) =
TP
TP + FN
(2.3.2)
Precision =
TP
TP + FP
(2.3.3)
F −measure = 2×Recall × Precision
Recall + Precision
(2.3.4)
Area under the ROC curve (AUC) is also used as a performance measurement. Figure
2.3.2 shows an example of an ROC curve. The closer the ROC curve is to the top left
corner, the better the performance of the classifier is. If the classifier is performing very
well, the true positive rate will increase and the AUC will be close to 1. If the classifier
randomly assigns samples to classes, the true positive rate will increase linearly with the
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false positive rate and the AUC will be around 0.5.
Figure 2.3.2: Example of ROC curve.
2.3.2 Cross Validation
Another approach for evaluating and testing a classification algorithm is cross validation,
in which an entire dataset is used to train and test that algorithm. It involves separating a
dataset into m equally sized groups of samples (m-folds). The model is trained on all folds
except one, and the created model is then tested on the left out fold. This process is re-
peated, and each fold will be given the opportunity to be left out and act as the test dataset.
Finally, the performance measures are averaged across all folds to estimate the model per-
formance on the problem. In this thesis, 10-fold cross validation is used to validate the
results.
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CHAPTER 3
Literature Review
This chapter reviews previous approaches related to the thesis’s. First, some existing
online tools used in translating mRNA code and detecting ORF are explained. Some studies
that identify proteins as biomarkers for prostate cancer diagnosis are then discussed.
3.1 Tools for mRNA Translation and ORF Finding
Regions of DNA that encode proteins are first transcribed into mRNA and are then
translated into protein. By examining a DNA sequence, one can determine the sequence of
amino acids that will appear in its final protein. In translation, codons of three nucleotides
define the amino acid that will be added next in the growing protein chain. Proteins are
formed from ORF, and by analyzing the ORF, we can predict the polypeptide chain that
might be produced during translation.
Typically only one ORF is used when translating a gene in Eukaryotes, and it is the
longest ORF. Once the ORF is found, the DNA sequence can be translated into its corre-
sponding amino acid sequence. However, discovering the actual ORF is not a straightfor-
ward task, especially when dealing with a very large number of long mRNA sequences.
Here, online translation tools and how they address ORFs are discussed. These tools
were tested using the transcript >hg19 chr7 89841000 89866992 +. The full se-
quence for the transcript can be found in Appendix A.
ORF Finder [38] is a translation tool available on the National Center for Biotechnology
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Information (NCBI) website. The tool identifies all possible ORFs from a sequence that
a user inserts in the giving text box. Figure 3.1.1 shows the input screen of ORF Finder,
while Figure 3.1.2 shows the query result. The user submits the translation request by
inserting the nucleotide sequence into the text area. The tool then returns the range of each
ORF along with its protein translation. As shown in Figure 3.1.2 , all sequences that are
located between a start codon and a stop codon are listed in descending order, based on
their length, along with their position. By choosing the required ORF, the corresponding
amino acid sequence appears in the left box. It is up to the user to choose which ORF is the
actual ORF, and then download it as a FASTA file. The user can select any detected ORFs
among the six reading frames for further information using BLAST.
Figure 3.1.1: Input screen of ORF Finder.
There is a shortage in the Web version of the ORF finder; the input sequence length
is limited to 50 kb long. Although there is a standalone version for this tool that does not
have such a limitation, it has to be requested from the authors. Another shortage related to
the tool input is that it accepts only one sequence to be translated and tested for potential
ORFs at a time.
The second translation tool is ExPASY (the Expert Protein Analysis System) by the
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Figure 3.1.2: Output screen of ORF Finder.
Swiss Institute of Bioinformatics [47]. It searches for ORFs in a sequence that a user enters
in the search box. Figure 3.1.3 shows the input screen of the tool where the sequence is
inserted in FASTA format.
The translation of all six reading frames appears with all potential ORFs. Figure 3.1.4
shows the translation of the sequence; the highlighted regions are potential ORFs. The user
has to select a reading frame and then select an ORF from that frame. Then, a new page
appears with an option to download the output translation as a FASTA file or to verify the
predicted polypeptide chain using BLAST. Similar to ORF finder, ExPASY does not have
the opttion of uploading an input file with multiple sequences, and does not identify the
actual ORF.
The third translation software is GetORF [14]. The tool allows one to enter a sequence
of data manually or to upload a FASTA file consisting of multiple sequences. It provides
the option to detect ORFs only in the positive strand or in both strands. GetORF outputs the
results in FASTA format, including the ORF identifier, the translated amino acid sequence,
and the ORF start and end sites. The main downside to this tool is that it identifies all
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Figure 3.1.3: input screen of ExPASY.
Figure 3.1.4: Output screen of ExPASY.
possible ORFs for a given sequence without discovering the actual ORF. Figures 3.1.5 and
3.1.6 show the input screen and the output result screen of this tool.
In conclusion, some existing platforms for finding ORFs and for translating RNA se-
quences were investigated. The advantages and disadvantages of each tool were described.
Some of the tools only translate one transcript at a time, while others have input length
limitations. No tool has the ability to discover the potential ORF; they detect all ORFs
instead. It could be very difficult for users to determine the potential ORF manually. For
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Figure 3.1.5: Input screen of GetORF.
Figure 3.1.6: Output screen of GetORF.
example, transcript NM 000059 that encodes gene BRCA2 contains thousands of ORFs in
its six reading frames.
In the thesis’s tool that was implemented to find the ORF, most of the concepts that
these previous tools follow were adopted, such as outputting the results in FASTA format.
However, all the disadvantages of each tool have been overcome.
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3.2 Using Proteins as Biomarkers
In mass spectrometry, surface-enhanced laser desorption/ionization (SELDI) provides a
sensitive system that analyzes protein masses within a sample [51]. SELDI is a strong tool
for analyzing proteins in a variety of biological materials such as tissue samples, blood,
urine, and other clinical samples. The technique is usually used as a diagnostic tool and
has been applied to diagnose cancer. Technological advances in mass spectrometry pose
challenges in computational methods to process the mass spectral data into predictive mod-
els that have clinical and biological significances. The biomarker discovery is achieved by
adopting machine learning techniques that allow a comparison of protein levels in serum
samples from healthy and diseased patients. Feature selection and classification techniques
are powerful tools for building predictive models from protein mass spectrometric profiles
and for identifying biomarker candidates. The best way to ultimately confirm the compu-
tational predictions results is through biological validation and identification of the under-
lying proteins [51]. Here, some approaches that discriminate between prostate cancer sam-
ples and normal samples using proteins and mass spectrometry technology are reviewed.
Qu et al. claimed that the Prostate-specific antigen (PSA) test is not an accurate biomarker
for early diagnoses of prostate cancer [38]. They developed a proteomic approach to
discriminating prostate cancer samples (PCA) from benign prostatic hyperplasia samples
(BPH) and normal age-matched samples. Their model detects and analyzes multiple pro-
teins to differentiate prostate cancer patients from non-cancer patients. The serum samples
used in the experiment were 197 prostate cancer samples (PCA), 92 benign prostatic hy-
perplasia samples (BPH), and 96 healthy samples. The samples were randomly separated
into a training set (325) and a test set (60), and were then analyzed using surface-enhanced
laser desorption or ionization (SELDI) mass spectrometry. Peak detection and alignment
were performed with the Ciphergen ProteinChip Software. 124 peaks, or features, were
detected and used as the training set to construct the classifiers for separating PCA group
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from the non-cancer groups. The classification model was then applied to the test set (30
PCA samples, 15 BPH samples, 15 healthy samples).
Two classifiers were implemented: the AdaBoost classifier and the Boosted Decision
Stump Feature Selection classifier (BDSFS). The BDSFS classifier is a decision tree classi-
fier with one split. This classifier is constructed on weighted examples and the classification
decision is made by voting in each round. 10-fold cross-validation was applied to estimate
the accuracy of the two classifiers. The first classifier, AdaBoost, gained perfect results
in discriminating prostate cancer samples from normal samples (it had 100% sensitivity
and specificity). The second classifier was combined with feature selection and resulted
in 21 features out of 500. It achieved a sensitivity and specificity of 97%. The authors
claimed that the combination of the SELDI protein profiling system and machine learning
algorithms could be used for the early detection or diagnosis of prostate cancer.
Wagner et al. discussed various classification approaches using protein profiles from
mass spectrometry experiments to discover protein biomarkers [51]. The authors aimed
to define peaks with a high likelihood of being biologically related to given disease state,
and identified some specific biomarkers of the disease. The prostate cancer samples were
obtained from the Eastern Virginia Medical School using SELDI-TOF mass spectrometry
from over 300 patients. The samples were grouped into four categories: benign prostatic
hyperplasia (BPH); early ,or localized, cancer; late , or metastasized, cancer; and controls.
The feature space was reduced by selecting the smallest set of peaks that yielded reasonable
classification results. The input vectors, or peaks, were decreased by using a filter-based
feature selection. The features were reduced from 779 to 220, and then a principal compo-
nent analysis was applied to further reduce the dimension of the data.
For classification, several algorithms were applied, such as quadratic discriminant func-
tions, nonparametric kernels, nearest neighbour methods, and linear support vector ma-
chines. The best results were obtained by applying a two-stage linear SVM classifier along
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with 13 peaks and cross validation. The average classification accuracy for the four-group
classification problem was 87%.
In a recent study, Taskin et al. demonstrated a model that classifies prostate cancer
samples using mass spectrometry data [49]. Samples from 322 men were used in the ex-
periment: 69 samples were malignant, 190 samples were benign, and 63 were normal. The
authors processed the dimensionality reduction in three stages. The first phase included a
filtering method, which employed some statistical tests to evaluate features and assigned a
score to each feature. The second phase used two different methods: the wavelet analysis
and the statistical moments; they were applied for comparison. In the wavelet analysis,
the discrete wavelet transform (DWT) was applied to the mass spectrometry data; approx-
imation coefficients were obtained. The obtained signal had a smoother form for the mass
spectrometry data as well as a low dimensionality. The statistical moments used filter-
ing methods for dimensionality reduction. The last phase for reducing the feature space
involved a feature transformation method, which was kernel partial least square (KPLS).
After the dimensionality reduction, the prostate data were classified using several al-
gorithms, such as k-nearest neighbour and SVMs. The classification was processed in two
steps with a 5-fold cross validation. In the first step, prostate samples were classified as
normal and cancerous. The cancerous samples were then classified as benign or malig-
nant. The classifiers’ performances for the two classification steps were 95.8% and 87.2%
respectively.
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CHAPTER 4
Materials and Methods
This chapter discusses the methodology used to implement the tool that finds the ORF
and reconstructs the potential protein isoform for every transcript. The protein isoforms
act as potential biomarkers for estimating prostate cancer progression stages. Furthermore,
some machine-learning techniques that were applied to the extracted protein isoforms to
find a group of them that are differentially expressed throughout prostate cancer’s stages
are illustrated.
4.1 The Dataset
The dataset used for this study was Long’s dataset, which can be found in NCBI’s
repository with the GEO accession no. GSE54460 [27]. The dataset involves roughly 490
billion base pair reads and deals with prostate cancer progression stages with a reasonable
number of samples in each stage. It contains 105 samples from 100 cancer patients. Table
4.1.1 shows the various stages of prostate cancer progression according to the American
Cancer Society, as well as the number of samples in each stage. The samples were grouped
according to their stage or substage and were labeled T1C, T2, T2A, T2B, T2C, T3, T3A,
T3B, and T4.
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Table 4.1.1: Stages of progression of prostate cancer according to the American Cancer
Society
Prostate
Cancer
Stage
Description Number of
Samples
T1c
The tumor is not detectable via imaging techniques.
Cancer is detected using a needle biopsy due to an
elevated serum prostate-specific antigen (PSA).
14
T2 The tumor is palpable, but confined to the prostate. 10
T2a
The tumor is in half, or less than half, of one of the
prostate glands’ two lobes.
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T2b
The tumor is in more than half of one lobe, but is not
in both lobes.
11
T2c
The tumor is in both lobes but confined within the
prostatic capsule.
30
T3
The tumor has started to spread out of the prostate
tissue.
2
T3a
The tumor has spread through the prostatic capsule
on one or both sides, but has not spread to the
seminal vesicles.
6
T3b
The tumor has invaded one or both of the seminal
vesicles.
8
T4 The tumor has spread to other organs. 1
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4.2 Preprocessing
Singireddy et al. [43] conducted a study on prostate cancer progression and gener-
ated transcripts for each sample in Long’s dataset. In their study, the samples files were
converted from SRA format to FASTQ format. TopHat2 [23] then was used to align the
reads to the reference genome (hg19), which resulted in identifying the accepted reads. The
accepted reads were fed to Cufflinks [50] to assemble the transcripts and to calculate their
FPKM values (fragments per kilobase of transcript per million mapped reads). FPKM is a
measurement unit for RNA-Seq expression.
Reconstructing the transcripts for all samples using Cufflinks generated 43,497 tran-
scripts or features, and some of these transcripts were non-coding RNAs. This study
focuses on coding RNAs (mRNA) that have the potential to code for proteins; thus non-
coding transcripts were removed and the number of features were reduced to 33,801 coding
transcripts. Figure 4.2.1 displays a sample table of the output data from Cufflinks that was
used. The columns represent the transcripts and their FPKM values and the rows represent
the samples, of which there were 105 samples in total. The last column, the class label,
shows the stage of prostate cancer for each sample.
4.3 Our Scheme for Classifying Stages
Even though we deal with several classes (stages of prostate cancer), we perform the
classification as a binary classification. Cancer progression means the cancerous tumor
continuously grows to the next stage. The progression develops in a specific order start-
ing with stage T1C and ending with stage T4 (T1c→T2→T2a→T2b→ T2c→ T3→
T3a→ T3b→ T4). This thesis focuses on finding differentially expressed protein iso-
forms between neighboring stages. For example, it compares samples from T1c with T2,
from T2 with T2a, from T2a with T2b, and so on.
Stages T3 and T4 contained a small number of samples, which affects the classifier
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Figure 4.2.1: Sample file from preprocessing phase, displaying some transcripts names
with their FPKM values for all samples, rows, and the class, last column.
generalization power; as a result, stages T3, T3a, T3b and T4 were merged into a new
group named T34. The expression variation in protein isoforms between the latter stages
of progression of T34 compared to T2c were studied. For the two stages, our experiment
involved 47 samples (30 and 17 samples for stages T2C and T34, respectively). The new
stage, T34, represented the critical transmission of the tumor from inside the prostate cap-
sule to outside the prostate.
4.4 Finding ORFs
A tool for finding ORFs and corresponding protein isoforms from RNA-Seq data was
implemented. A detailed description of the tool mechanism is illustrated here; Figure 4.4.2
shows a schematic view of the proposed method. The proposed tool reads transcripts and
performs the whole process on each transcript individually, then subsequently considers
the next sequences in the input file. It translates all six reading frames into amino acid
sequences using the codon table. Then all possible ORFs are obtained, and only the longest
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one in each frame is held. Finally, the longest ORF among the six candidates is considered
the potential ORF for the transcript.
The original sequence is read from (5’→ 3’) to obtain the three positive reading frames.
In order to obtain the three negative reading frames, one need to obtain the complemen-
tary strand of the positive DNA strand. As DNA is antiparallel, we also need the reverse
complement sequence to keep the 5’ and 3’ ends correctly oriented.
Figure 4.4.1 shows an example of obtaining the reversed complementary sequence. In
the example, the original sequence is read from (5’→ 3’) and the three positive reading
frames are obtained. Two steps are done to obtain the three negative frames. First, the tool
finds the complementary sequence for the original sequence by exchanging each (A, T or
U, C, G) with (T, U or T, G, C). Second, the complementary sequence is reversed, so it can
be read (5’→ 3’), in the same manner as the first strand.
Figure 4.4.1: Obtaining complementary sequence from original mRNA sequence.
After that, the tool scans each reading frame individually and detects all possible ORFs,
namely the protein isoforms. The ORF extends from the start codon AUG and continues
until the reading frame defined by the start codon is terminated by one of the three trans-
lation stop codons UGA, UAA, or UAG. The translation process begins by interpreting the
start codon into Methionine, and includes it in the polypeptide chain. When a start codon
(AUG) is found in the middle of the ORF, it is translated into Methionine, and the trans-
lation process continues until a stop codon terminates it. In the next step, by comparing
the length of the detected isoforms in the six frames, the tool selects the longest one as the
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most relevant isoform for the given transcript [54].
Figure 4.4.2: Schematic view of proposed tool for translating and identifying the actual
ORF.
4.5 New Measurement for Quantification
In any given cell, only a fraction of its genes are turned on at a given time; this is the
concept of gene expression. Any change in the perfectly controlled process will affect the
cell and may cause diseases such as cancer. In other words, irregular expressions in tumors
make cancer cells different from healthy cells.
Gene expression can be measured using different methods; RNA-Seq data was used in
36
this work. the thesis’s interest is measuring the expressions of protein isoforms that were
constructed using the proposed tool. The expression level is calculated for isoforms in
each sample, and by comparing different samples, we can extract some information about
prostate cancer progression.
To estimate the number of supporting fragments, a new measurement derived from
FPKM value is considered. The new quantification method makes the measurement of
abundance more accurately related to only those fragments that are located within that
region. FPKM values for all transcripts are computed by Cufflinks, shown in Figure 4.2.1.
The FPKM unit considers all fragments within a transcript, while only the fragments
that fall within the actual ORF region need to be taken into the account for this thesis. If
L(transcript) is the length of a given transcript and L(ORF) is the length of its ORF, then
AFPKM =
L(ORF )
L(transcript)
× FPKMvalue (4.5.1)
Figure 4.5.1 shows an example of how one finds abundance with the proposed measure.
The new FPKM value is called adapted FPKM (AFPKM). It takes into account the propor-
tion of the transcript that is actually translated into protein and ignores the non-coding part.
Figure 4.5.1: Use of fragments to measure abundance of protein isoforms.
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4.6 Feature Selection and Classification
With 33,801 transcripts or features, it is important to reduce the dimensionality of
the problem by applying feature selection to improve the classification performance. For
this, the mRMR feature selection method [33] was used. The features here are the protein
isoforms with their AFPKM values; and the class labels are the prostate cancer stages.
Figure 4.6.1 shows the pipeline of the machine-learning approach. In the figure, there
is a table that involves transcripts and their FPKM values for a pair of stages. The table acts
as input to the proposed tool to identify the ORF for each transcript and obtain the corre-
sponding protein isoforms. The feature selection filters out noisy and redundant features.
The filtered features are sent to the classification algorithms to detect protein isoforms, or
biomarkers, that are differentially expressed.
Weka was used to perform the feature selection and the classification [18]. It is a well-
known data mining tool developed at the University of Waikato, and it is commonly used
in bioinformatics.
4.6.1 Feature Selection
Among 33,801 protein isoforms or features per sample, there is a significant number
of irrelevant and noisy transcripts that affect the classification’s accuracy. They make the
classification algorithms perform poorly and consume a large amount of memory and time.
Thus, feature selection technique was used to reduce the dimensionality of the problem and
to remove features that degraded classification performance.
The feature selection technique mRMR [33] was applied; it is a wrapper method used
to select a subset of features. MRMR embeds a classification algorithm to choose the most
relevant features. The algorithm mRMR incorporates a classifier to determine the best
subset of features that can classify the samples. Different classifiers were experimented
with, and Naive Bayes gave the best results with default parameters.
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Figure 4.6.1: Pipeline of our method for prostate cancer progression classifications.
4.6.2 Classification
After feature selection, different classification algorithms that discriminate between
prostate cancer stages were applied. Various classifiers that classify the samples based
on the classification rules learned in the training phase were tested. SVM [11] was used,
and the linear, polynomial, and radial basis function kernels were experimented with grid
search optimization. Random forest [4] and the J48 decision tree [39] were also tested.
Additionally, the Naive Bayes classifier was used to compare its performance with all other
classifiers. Finally, the differentially expressed protein isoforms in the desired stages were
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obtained. To evaluate the classifiers and maintain their generalization capability, a 10-
fold cross-validation was used. Chapter 5 assesses the performance of the classifiers using
several performance measures.
4.6.3 Comparison Between Using Protein Isoforms as Features and
Using Transcripts as Features
In a previous study [43], Singireddy et al. used the same dataset used in this thesis;
the dataset include 105 prostate cancer samples along with their FPKM value. They ap-
plied some feature selection algorithms on the pairwise stage T2c-T34 which consists of
47 samples. They found a set of 11 transcripts shown in Figure 4.6.2, that were able to
discriminate stage 2 of prostate cancer from subsequent stages with very high accuracy.
Two experiments were conducted to test the significance of using protein isoforms in-
stead of whole transcripts as biomarkers for prostate cancer progression. First, classifica-
tion results were compared with [43] results for the pairwise stage (T2c-T34). Second,
we fed our tool with those 11 transcripts to find the actual ORFs in each. Then AFPKM
was computed using the Formula 4.5.1. Finally, different classifiers were run and their
performances were evaluated using protein isoforms, compared to transcripts. .
Figure 4.6.2: Set of 11 transcripts for discriminating stage 2 of prostate cancer from stages
3 and 4 obtained by Singireddy [43].
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CHAPTER 5
Results and Discussion
This chapter discusses the results of the approach in finding biomarkers for prostate
cancer progression. Protein isoforms extracted using the proposed tool were processed us-
ing the feature selection technique. The feature vectors were input to the classifiers, and the
classification performance was graphically visualized. Classification and feature selection
algorithms were employed to find differentially expressed protein isoforms. Classification
performance measures for pairwise stages are discussed. Furthermore, an experiment was
conducted to test the significance of using protein isoforms instead of whole transcripts to
differentiate between prostate cancer stages. The classification performances were com-
pared using protein isoforms and transcripts. Finally, the biological significances of some
selected protein isoforms are demonstrated.
5.1 Generating Protein Isoforms
A tool for finding ORF and reconstructing protein isoforms was implemented. The
tool was fed with 33,801 transcripts to identify the potential proteins coded in them. The
first prototype of the proposed tool was been written in Python; hence, it is easy to install
on many different platforms. Unlike existing tools, the proposed tool can process several
transcripts at a time and obtain the actual ORF for each of them. The main module accepts
the transcripts in FASTA format as inputs and then outputs two files. One of the files
contains sequences in FASTA format, which include an identifier for the sequence, and the
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amino acid sequence of the predicted protein isoform. The FASTA file can be searched
in a protein sequence database to similar proteins using BLASTP, for example. Figure
5.1.1 shows an example for the first output file. The second file contains more detailed
information, such as the sequence identifier; the polypeptide chains for all six frames;
identified ORFs for all six frames along with their lengths; and the detected ORF (the
potential protein isoform) for a transcript; and its position in the sequence. The amino acid
sequences in the generated files have the same order as the input file.
The identified protein isoforms are used as features that incorporate different machine
learning techniques to identify a small group of isoforms that are differentially expressed
in the various stages of prostate cancer progression.
Figure 5.1.1: Sample of output file containing the ORF.
5.2 Feature Selection Results
The feature selection method mRMR was applied; it resulted in identifying 36 protein
isoforms for the set of all pairwise stages. Figure 5.2.1 shows the transcripts IDs for the
differentially expressed protein isoforms across different stages. The number of selected
protein isoforms for pairwise stages T1c-T2, T2-T2a, T2a-T2b, T2b-T2c, T2c- T3a, T3a-
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T3b, and T2c-T34 are 3, 8, 5, 3, 3, 4, and 10 respectively. More information about the
selected protein isoforms such as the location (their locus) in the corresponding chromo-
some and gene name can be found in Appendix B. The classification efficiency using the
selected isoforms is discussed for each pairwise stage in the following section.
Figure 5.2.1: Transcripts IDs for differentially expressed protein isoforms across different
stages.
5.3 Classification Results
The selected features by mRMR were employed to build a classification model for all
pairwise stages. Bayes Net, Naive Bayes, JRip, random tree, and random forest were tested.
The accuracy range for all classifiers was between 82.98% and 100% with an average of
93.46%. The Bayes Net classifier performed significantly for three pairwise stages out of
seven by predicting all samples correctly.
Figures 5.3.1 and 5.3.2 show the recalls and precisions of different classifiers using
the selected protein isoforms. The x-axis represents pairwise stages of prostate cancer
progression while the y-axis displays the efficiency measurement used. As shown in the
figure, the recall of the Bayes Net classifier outperformed other classifiers for most of the
pairwise stages. For stages (T1c-T2), (T2-T2a), (T3a-T3b), and (T2c-T34), Bayes Net
achieved a perfect recall (its recall=1). Regarding Precision, all the classifiers achieved
ideal precision (a precision = 1) for distinguishing between sub-stages T3a-T3b.
The area under the ROC curve (AUC) results was visualized to differentiate between
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Figure 5.3.1: Classification performance for all pair-wise stages using recall as perfor-
mance measurement.
Figure 5.3.2: Classification performance for all pair-wise stages, using precision as perfor-
mance measurement.
prostate cancer stages. Figure 5.3.3 shows the classifiers’ performance considering the
AUC value. For T2c-T34, AUC for the Bayes Net and Naive Bayes classifiers reached
0.99, while it reached 0.95 for random forest.
Regarding F-meaure, the classifiers’ results can be seen in Table 5.3.1. The F-measure
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Figure 5.3.3: Classification performance for all pair-wise stages, using AUC as perfor-
mance measurement.
for Naive Bayes is noticeably high for all pairwise stages (above 0.90). Additionally, Naive
Bayes achieved perfect results for the pairwise stages (T1c-T2), (T2-T2a), and (T3a-T3b).
(T2b-T2c) were the hardest pair to be classified by all classifiers with an F-measure = 0.82
on average. Similar to all other performance measurements, (T3a-T3b) were accurately
classified by most of the classifiers using F-measure.
Table 5.3.1: Classification performance for all pair-wise stages using F-measure as mea-
surement.
Stages Bayes Net Naive
Bayes
JRip Random
Tree
Random
Forest
T1c-T2 1 0.93 0.89 0.96 0.96
T2-T2a 1 0.95 0.82 0.80 0.95
T2a-T2b 0.94 0.94 0.92 0.91 0.92
T2b-T2c 0.76 0.95 0.74 0.90 0.76
T2c-T3a 0.93 0.98 0.97 0.97 0.98
T3a-T3b 1 1 0.93 1 1
T2c-T34 0.98 0.98 0.87 0.91 0.95
In addition, SVM was tested with linear, ploynomial, and RBF kernels. Figures 5.3.4
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and 5.3.5 show the accuracy and AUC values of the SVM classifiers for all stages. The
accuracy for all classifiers throughout all pairwise stages varied between 79.4% and 97.8%
with an average of 91.06%.
The AUC value for the pairwise stage (T2c-T3a) was 0.97 by SVM-linear, SVM-
ploynomial, and SVM-RBF. Similarly, (T3a-T3b) achieved AUC=0.94 with all classi-
fiers. The SVM with the RBF kernel achieved the best performance for (T2a-T2b) with
an AUC=0.87, while the other kernels’ scores were 0.73.
Figure 5.3.4: Performance of SVM classifiers with selected protein isoforms, using accu-
racy as measurement.
In general, the results illustrate that the selected protein isoform could be used to differ-
entiate samples across all stages with a high level of accuracy. The protein isoforms could
be investigated further as potential biomarkers of prostate cancer progression.
5.4 Results for Using Protein Isoforms Versus Transcripts
Figure 5.4.1 shows the classifiers’ performances and compares using transcripts iden-
tified by [43] and using our protein isoforms. As shown in the figure, for most of the clas-
sifiers, the thesis’s proposed method provides superior performance while using a smaller
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Figure 5.3.5: Performance of SVM classifiers with selected protein isoforms, using AUC
as performance measurement.
group of biomarkers. Using ORFs detected by our model for discriminating T2c-T34 stages
almost always achieved better results than using original transcripts. J48 performance im-
proved by around 10% when using protein isoforms. Only the SVM-Polynomial achieved
higher accuracy when using transcripts instead of using protein isoforms, with 91.2% for
the former and 84.5% for the latter.
In the second experiment, the performance of the transcripts was compared to the previ-
ous study with their ORFs. The ORF for each transcript was found and applied to different
classifiers using them. The performance of the 11 identified transcripts was compared with
the performance of their corresponding ORFs for discriminating between stages T2C and
T34 of prostate cancer. Figure 5.4.2 shows the classification accuracy for the comparison
between using the original transcripts (the FPKM values) and the ORFs detected in them
(the AFPKM values). As shown in the figure, using protein isoforms instead of RNA tran-
scripts boosts the classification performance in some classifiers, using default parameters
such as SVM-linear and SVM-polynomial.
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Figure 5.4.1: Comparison between this thesis’s protein isoforms and transcripts reported in
[43].
5.5 Discussion and Biological Significance
The 36 transcripts shown in Figure 5.2.1 were obtained using the feature selection
technique mRMR. It was found that a great proportion of the detected isoforms or genes
are associated with cancer or other diseases. In this section, the biological significance of
selected biomarkers is highlighted.
Studies [10] and [42] demonstrated that CREB was involved in tumor initiation, pro-
gression, and metastasis. Another study focused on utilizing the CREB protein for thera-
peutic purposes in cancer [56]. The authors stated that CREB was a critical regulator of cell
differentiation and proliferation. They suggested that overexpression and over-activation of
the protein were noticed in diverse cancer tissues including prostate cancer. However, the
down-regulation of CREB in cancer cells inhibits tumor growth and induces apoptosis.
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Figure 5.4.2: Comparison between using transcripts with original FPKM [43] and the same
transcripts with AFPKM, and its effect in classification performance for (T2c-T34).
The protein isoform detected in the HIST1H4F gene is a member of the H4 histone
family. Fraga et al. [17] found that cancer cells had changed forms of histone H4. The
changes appeared early in cancer and accumulated during the tumor progression. The
authors suggested that the changing of histone H4 is a common characteristic of human
tumor cells.
The Gse1 coiled-coil protein (GSE1) is expressed differentially between stages T2a-
T2b. Chai et al. state that the GSE1 protein is overexpressed in breast cancer, and the
silencing of GSE1 remarkably suppresses breast cancer cells’ proliferation, migration, and
invasion. They concluded that GSE1 plays an important role in promoting breast cancer
progression [7].
49
In the pair (T2b-T2c), different expression levels for the Biglycan protein were detected.
It has been shown that high a expression level of Biglycan is present in various cancers
such as endometrial [26], pancreatic [2], and gastric [21]. Xing et al. explored the function
of Biglycan in colon cancer progression. Decreasing the expression levels of the protein
prevents colon cancer cell migration and invasion. In addition, down regulating Biglycan
induces apoptosis in cancerous cells [57].
Payne et al. identified the protein HIST1H4K (which is from the same family as the
nominated biomarker HIST1H4L) as a prostate cancer biomarker. The biomarker showed
minimal correlation with PSA, which is the target protein in any typical prostate cancer test
[42]. The authors suggested integrating HIST1H4K with a PSA test to diagnose prostate
cancer in patients.
HSP70 belongs to a class of proteins called heat shock proteins (HSPs). In general,
HSPs’ expression levels are higher in cancer cells. The HSP70 protein is highly expressed
in some cancers; However, its reduction has led to tumor regression [34]. Murphy et al.
conducted an intensive study on HSP70 and its role in cancer and concluded that HSP70
gene can function as an oncogene [29]. There are many studies that discuss HSP70’s as-
sociation with cancer [5], [9]. One study focused on investigating HSP70 as a biomarker
for prostate cancer [1]. The authors suggested that HSP70 could be a potential biomarker
for prostate cancer. Their experimental results showed that HSP70 was overexpressed in
patients’ plasma, whereas the patients’ PSA levels were normal.
It has been shown that changes in the PTMA expression (the protein in the transcript
NM 001099285) is involved in the development and progression of prostate cancer [46].
Another study demonstrated that lower expression levels of Prothymosin alpha (PTMA)
were linked to the inhibition of prostate cancer initiation [19].
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In order to obtain a further insight, the hypothesis that the PTMA expression increases
with the progression of prostate cancer was investigated for this thesis. Figure 5.5.1 shows
the expression trend level of the ten chosen isoforms between stages T2C and T34. The
x-axis represents the 10 identified protein isoforms, while the y-axis represents the median
of AFPKM values across different samples from each group. As shown in the figure, the
expression level for the protein isoform that we identified in PTMA was by far higher in
stage T34, compared to T2c (1.3 and 0.1 respectively).
Figure 5.5.1: Comparison between median of AFPKM values for 10 selected protein iso-
forms in stages T2C and T34 of prostate cancer.
Transcript NM 001099285 in particular had a significant FPKM variation between
T2C and T34. Suzuki et al. found that PTMA’s expression was involved in human prostate
cancers progression [46]. The authors conducted an experiment in vitro and studied autopsy
cases of those who died of prostate cancer. The study covered samples of different prostate
cancer stages as well as benign samples. The results showed that the PTMA expression
level correlated with prostate cancer development; the levels were the highest in the autopsy
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cases.
In all of the thesis’s samples, a sudden increase in the expression of PTMA was experi-
enced as the tumor progressed across later stages. The literature review about Prothymosin
(PTMA) supports the thesis’s result and makes the protein a potential biomarker for prostate
cancer progression monitoring between stage 2 and subsequent stages. It is worth further
investigation.
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CHAPTER 6
Conclusion and Future Work
6.1 Contributions
An open reading frame (ORF) is a continuous sequence of codons that begins with a start
codon and ends with a codon. Finding ORFs that correspond to a given mRNA transcript
is a major step in reconstructing protein isoforms and is vital for a better understanding
of RNA alternative splicing effects in diseases like cancer. Prostate cancer is one of the
most widespread types of cancer, especially in developed countries. Finding biomarkers is
a vital step in the early diagnosis of the tumor and in classifying stages in the progression
of the disease.
In this work, a new tool that can find ORFs and protein isoforms for any given transcript
was proposed. One of the advantages of the tool over other existing tools is the ability to
identify the actual ORF for a transcript. Moreover, it obtains the ORFs for more than one
transcript at a time, which eliminates the burden of manually processing of each transcript.
A model that uses RNA-Seq data and machine learning techniques to detect prostate
cancer progression was also proposed. The tool was used to find the ORF for a given
mRNA sequence and to then identify the corresponding protein isoform. Some machine
learning techniques employed the generated protein isoforms, and the model was able to
discriminate between stages of prostate cancer with a very high accuracy.
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6.2 Future Work
Possible extensions of this work include improving the quantification method by in-
vestigating more precise statistical measures for counting only the relevant reads inside
the ORF. Several applications of this tool involve a standalone tool for public use and an
embedding of integration with a variety of databases such as UniProt.
Further investigations could be done on functional and interactomics analyse of the
relevant proteins and their interactions with other proteins and molecules. Such integrations
will result in insight about the biological aspects of the disease that are not captured by
conventional approaches, which cover up to RNA transcripts or merely genes. Moreover,
an investigation of additional classifiers and feature selection algorithms may improve the
results.
The results achieved by the proposed model are closely related to prostate cancer. How-
ever, having a larger number of samples in each progression stage would improve the
model, and further biological experiments are highly recommended. Finally, the model
could be extended to other types of cancers and their progression stages.
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APPENDIX A
Supplementary Information
A.1 Input Sequence for Translation Tools
The following is the sequence for the transcript >hg19 chr7 89841000 89866992 +
used in Chapter 3 as an input for the translation tools.
>hg19 chr7 89841000 89866992 +
GCCCCCTCCGAGCTCCCCGACTCCTCCCCGCGCTCCACGGCTCTTCCC
GACTCCAGTCAGCGTTCCTCGGGCCCTCGGCGCCACGAGCTGTCCGG
GCACGCAGCCCCTAGCGGCGCGTCGCTGCCAAGCCGGCCTCCGCGCG
CCTCCCTCCTTCCTTCTCCCCTGGCTGTTCGCGATCCAGCTTGGGTAGG
CGGGGAAGCAGCTGGAGTGCGACCGCCGCGGCAGCCACCCTGC
AACCGCCAGTCGGAGGTGCAGTCCGTAGGCCCTGGCCCCCGGGTGGGC
CCTTGGGGAGTCGGCGCCGCTCCCGGGGAGCTGCAAGGCTCGCCCCTG
CCCGGCGTGGAGGGCGCGGGGGGCGCGGAGAAAGTGAAGAGAGGAA
ATTGGAAAATTGTGAGTGGACCTTCTGATACTGCTCCTCCTTGCGTGGAA
AAGGGGAAAGAACTGCATGCATATTATTCAGCGTCCTATATTCAAAGGATA
TTCTTGGTGATCTTGGAAGTGTCCGTATCATGGAATCAATCTCTATGATG
GGAAGCCCTAAGAGCCTTAGTGAAACTTTTTTACCTAATGGCATAAATGGT
ATCAAAGATGCAAGGAAGGTCACTGTAGGTGTGATTGGAAGTGGAGA
TTTTGCCAAATCCTTGACCATTCGACTTATTAGATGCGGCTATCATGTGGTC
ATAGGAAGTAGAAATCCTAAGTTTGCTTCTGAATTTTTTCCTCATGTGGTAGA
62
TGTCACTCATCATGAAGATGCTCTCACAAAAACAAATATAATATTTGTTGCT
ATACACAGAGAACATTATACCTCCCTGTGGGACCTGAGACATCTG
CTTGTGGGTAAAATCCTGATTGATGTGAGCAATAACATGAGGATAAA
CCAGTACCCAGAATCCAATGCTGAATATTTGGCTTCATTATTCCCA
GATTCTTTGATTGTCAAAGGATTTAATGTTGTCTCAGCTTGGGCAC
TTCAGTTAGGACCTAAGGATGCCAGCCGGCAGGTTTATATATGCAGCA
ACAATATTCAAGCGCGACAACAGGTTATTGAACTTGCCCGCCAGTT
GAATTTCATTCCCATTGACTTGGGATCCTTATCATCAGCCAGAGAGA
TTGAAAATTTACCCCTACGACTCTTTACTCTCTGGAGAGGGCCAGTGGT
GGTAGCTATAAGCTTGGCCACATTTTTTTTCCTTTATTCCTTTGTCA
GAGATGTGATTCATCCATATGCTAGAAACCAACAGAGTGACTTTTAC
AAAATTCCTATAGAGATTGTGAATAAAACCTTACCTATAGTTGCCATTA
CTTTGCTCTCCCTAGTATACCTCGCAGGTCTTCTGGCAGCTGCTTATC
AACTTTATTACGGCACCAAGTATAGGAGATTTCCACCTTGGTTGGA
AACCTGGTTACAGTGTAGAAAACAGCTTGGATTACTAAGTTTTTTC
TTCGCTATGGTCCATGTTGCCTACAGCCTCTGCTTACCGATGAGA
AGGTCAGAGAGATATTTGTTTCTCAACATGGCTTATCAGCAGGTTCA
TGCAAATATTGAAAACTCTTGGAATGAGGAAGAAGTTTGGAGAATT
GAAATGTATATCTCCTTTGGCATAATGAGCCTTGGCTTACTTTCCCTCC
TGGCAGTCACTTCTATCCCTTCAGTGAGCAATGCTTTAAACTGGA
GAGAATTCAGTTTTATTCAGTCTACACTTGGATATGTCGCTCTGC
TCATAAGTACTTTCCATGTTTTAATTTATGGATGGAAACGAGCTTT
TGAGGAAGAGTACTACAGATTTTATACACCACCAAACT
TTGTTCTTGCTCTTGTTTTGCCCTCAATTGTAATTCTGGGTAAGATTAT
TTTATTCCTTCCATGTATAAGCCGAAAGCTAAAACGAATTAAAAAAG
GCTGGGAAAAGAGCCAATTTCTGGAAGAAGGTATGGGAGGA
ACAATTCCTCATGTCTCCCCGGAGAGGGTCACAGTAATGTGAT
63
GACAAATGGTGTTCACAGCTGCCATATAAAGTTCTACTCATGCCA
TTATTTTTATGACTTCTACGTTCAG
TTACAAGTATGCTGTCAAATTATCGTGGGTTGAAACTTGTTAAATGAGAT
TTCAACTGACTTAGTGATAGAGTTTTCTTCAAGTTAATTTTCACAAATGT
CATGTTTGCCAATATGAATTTTTCTAGTCAACATATTATTGTAATTTAGG
TATGTTTTGTTTTGTTTTGCACAACTGTAACCCTGTTGTTACTTTATATT
TCATAATCAGGCAAAAATACTTACAGTTAATAATATAGATATAATGTTAA
AAACAATTTGCAAACCAGCAGAATTTTAAGCTTTTAAAATAATTCAATGG
ATATACATTTTTTTCTGAAGATTAAGATTTTAATTATTCAACTTAAAAAG
TAGAAATGCATTATTATACATTTTTTTAAGAAAGGACACGTTATGTTAGC
ATCTAGGTAAGGCTGCATGATAGCATTCCTATATTTCTCTCATAAAATAG
GATTTGAAGGATGAAATTAATTGTATGAAGCAATGTGATTATATGAAGAG
ACACAAATTAAAAAGACAAATTAAACCTGAAATTATATTTAAAATATATT
TGAGACATGAAATACATACTGATAATACATACCTCATGAAAGATTTTATT
CTTTATTGTGTTACAGAGCAGTTTCATTTTCATATTAATATACTGATCAG
GAAGAGGATTCAGTAACATTTGGCTTCCAAAACTGCTATCTCTAATACGG
TACCAATCCTAGGAACTGTATACTAGTTCCTACTTAGAACAAAAGTATCA
AGTTTGCACACAAGTAATCTGCCAGCTGACCTTTGTCGCACCTTAACCAG
TCACCACTTGCTATGGTATAGGATTATACTGATGTTCTTTGAGGGATTCT
GATGTGCTAGGCATGGTTCTAAGTACTTTACTTGTATTATCCCATTTAAT
ACTTAGAACAACCCCGTGAGATAAGTAGTTATTATCCTCATTTTACACAT
GAGGGACCGAAGGATAGAAAAGTTATTTTTCAAAGGTCTTGCAGTTAATA
AATGGCAGAGTGAGCATTCAAGTCCAGGTAGTCATATTCCAGAGGCCACG
GTTTTAACCACTAGGCTCTAGAGCTCCCGCCGCGCCCCTATGCATTATGT
TCACAATGCCAATCTAGATGCTTCCTCTTTTGTATAAAGTCACTGACATT
CTTTAGAGTGGGTTGGGTGCATCCAAAAATGTATAAAAATATTATTATAA
TAAACTTATTACTGCTTGTAGGGTAATTCACAGTTACTTACCCTATTCTT
64
GCTTGGAACATGAGCCTGGAGACCCATGGCAGTCCATATGCCTCCCTATG
CAGTGAAGGGCCCTAGCAGTGTTAACAAATTGCTGAGATCCCACGGAGTC
TTTCAAAAATCTCTGTAGAGTTAGTCTTCTCCTTTTCTCTTCCTGAGAAG
TTCTCCTGCCTGCATAACCATTCATTAGGGAGTACTTTACAAGCATGAAG
GATATTAGGGTAAGTGGCTAATTATAAATCTACTCTAGAGACATATAATC
ATACAGATTATTCATAAAATTTTTCAGTGCTGTCCTTCCACATTTAATTG
CATTTTGCTCAAACTGTAGAATGCCCTACATTCCCCCCACCCCAATTTGC
TATTTCCTTATTAAAATAGAAAATTATAGGCAAGATACAATTATATGCGT
TCCTCTTCCTGAAATTATAACATTTCTAAACTTACCCACGTAGGTACTAC
TGAATCCAACTGCCAACAATAAAAAGACTTTTATTTAGTAGAGGCTACCT
TTCCCACCAGTGACTCTTTTTCTACAACTGCCTTGTCAGTTTGGTAATTC
ACTTATGATTTTCTAATGTTCTCTTGGTGAATTTTATTATCTTGTACCCT
CTTTTTTTTTTTTTTTTTTTTTAAAGACAGAGTCTTGCTCTGTCACCCAG
GCTGGAGTGCAGTGGCACGATCTCGGCTCACTGCAAGCTCTGCCTCCCGG
GTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGT
GCCCGCCACCATGCCCGGCTGATTTCTTTTTGTATTTTTAGTAGAGACGG
AGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCC
GCCCGCCTTGGCCTCCAAAGTGCTGGGATTACAGGTGTGAGCTACCGCGC
CCGGCCTATTATCTTGTACTTTCTAACTGAGCCCTCTATTTTCTTTATTT
TAATAATATTTCTCCCCACTTGAGAATCACTTGTTAGTTCTTGGTAGGAA
TTCAGTTGGGCAATGATAACTTTTATGGGCAAAAACATTCTATTATAGTG
AACTAATGAAAATAACAGCGTATTTTCAATATTTTCTTATTCCTTAAATT
CCACTCTTTTAACACTATGCTTAACCACTTAATGTGATGAAATATTCCTA
AAAGTTAAATGACTATTAAAGCATATATTGTTGCATGTATATATTAAGTA
GCCGATACTCTAAATAAAAATACCACTGTTACAGATAAATGGGGCCTTTA
AAAATATGAAAAACAAACTTGTGAAAATGTATAAAAGATGCATCTGTTGT
TTCAAATGGCACTATCTTCTTTTCAGTACTACAAAAACAGAATAATTTTG
65
AAGTTTTAGAATAAATGTAATATATTTACTATAATTCTAAATGTTTAAAT
GCTTTTCTAAAAATGCAAAACTATGATGTTTAGTTGCTTTATTTTACCTC
TATGTGATTATTTTTCTTAATTGTTATTTTTTATAATCATTATTTTTCTG
AACCATTCTTCTGGCCTCAGAAGTAGGACTGAATTCTACTATTGCTAGGT
GTGAGAAAGTGGTGGTGAGAACCTTAGAGCAGTGGAGATTTGCTACCTGG
TCTGTGTTTTGAGAAGTGCCCCTTAGAAAGTTAAAAGAATGTAGAAAAGA
TACTCAGTCTTAATCCTATGCAAAAAAAAAAATCAAGTAATTGTTTTCCT
ATGAGGAAAATAACCATGAGCTGTATCATGCTACTTAGCTTTTATGTAAA
TATTTCTTATGTCTCCTCTATTAAGAGTATTTAAAATCATATTTAAATAT
GAATCTATTCATGCTAACATTATTTTTCAAAACATACATGGAAATTTAGC
CCAGATTGTCTACATATAAGGTTTTTATTTGAATTGTAAAATATTTAAAA
GTATGAATAAAATATATTTATAGGTATTTATCAGAGATGATTATTTTGTG
CTACATACAGGTTGGCTAATGAGCTCTAGTGTTAAACTACCTGATTAATT
TCTTATAAAGCAGCATAACCTTGGCTTGATTAAGGAATTCTACTTTCAAA
AATTAATCTGATAATAGTAACAAGGTATATTATACTTTCATTACAATCAA
ATTATAGAAATTACTTGTGTAAAAGGGCTTCAAGAATATATCCAATTTTT
AAATATTTTAATATATCTCCTATCTGATAACTTAATTCTTCTAAATTACC
ACTTGCCATTAAGCTATTTCATAATAAATTCTGTACAGTTTCCCCCCAAA
AAAGAGATTTATTTATGAAATATTTAAAGTTTCTAATGTGGTATTTTAAA
TAAAGTATCATAAATGTAATAAGTAAATATTTATTTAGGAATACTGTGAA
CACTGAACTAATTATTCCTGTGTCAGTCTATGAAATCCCTGTTTTGAAAT
ACGTAAACAGCCTAAAATGTGTTGAAATTATTTTGTAAATCCATGACTTA
AAACAAGATACATACATAGTATAACACACCTCACAGTGTTAAGATTTATA
TTGTGAAATGAGACACCCTACCTTCAATTGTTCATCAGTGGGTAAAACAA
ATTCTGATGTACATTCAGGACAAATGATTAGCCCTAAATGAAACTGTAAT
AATTTCAGTGGAAACTCAATCTGTTTTTACCTTTAAACAGTGAATTTTAC
ATGAATGAATGGGTTCTTCACTTTTTTTTTAGTATGAGAAAATTATACAG
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TGCTTAATTTTCAGAGATTCTTTCCATATGTTACTAAAAAATGTTTTGTT
CAGCCTAACATACTGAGTTTTTTTTAACTTTCTAAATTATTGAATTTCCA
TCATGCATTCATCCAAAATTAAGGCAGACTGTTTGGATTCTTCCAGTGGC
CAGATGAGCTAAATTAAATCACAAAAGCAGATGCTTTTGTATGATCTCCA
AATTGCCAACTTTAAGGAAATATTCTCTTGAAATTGTCTTTAAAGATCTT
TTGCAGCTTTGCAGATACCCAGACTGAGCTGGAACTGGAATTTGTCTTCC
TATTGACTCTACTTCTTTAAAAGCGGCTGCCCATTACATTCCTCAGCTGT
CCTTGCAGTTAGGTGTACATGTGACTGAGTGTTGGCCAGTGAGATGAAGT
CTCCTCAAAGGAAGGCAGCATGTGTCCTTTTTCATCCCTTCATCTTGCTG
CTGGGATTGTGGATATAACAGGAGCCCTGGCAGCTGTCTCCAGAGGATCA
AAGCCACACCCAAAGAGTAAGGCAGATTAGAGACCAGAAAGACCTTGACT
ACTTCCCTACTTCCACTGCTTTTTCCTGCATTTAAGCCATTGTAAATCTG
GGTGTGTTACATGAAGTGAAAATTAATTCTTTCTGCCCTTCAGTTCTTTA
TCCTGATACCATTTAACACTGTCTGAATTAACTAGACTGCAATAATTCTT
TCTTTTGAAAGCTTTTAAAGGATAATGTGCAATTCACATTAAAATTGATT
TTCCATTGTCAATTAGTTATACTCATTTTCCTGCCTTGATCTTTCATTAG
ATATTTTGTATCTGCTTGGAATATATTATCTTCTTTTTAACTGTGTAATT
GGTAATTACTAAAACTCTGTAATCTCCAAAATATTGCTATCAAATTACAC
ACCATGTTTTCTATCATTCTCATAGATCTGCCTTATAAACATTTAAATAA
AAAGTACTATTTAATGATTTAACTTCTGTTTTGAAATGTTGTATACACGT
GGATTTTTTTCTCATTAAATAATAATTCTAGTA
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APPENDIX B
Supplementary Results
B.1 Protein Isoforms Selected by mRMR Feature Selec-
tion in All Pairwise Stages
Table B.1.1: Details about selected protein isoforms from Long’s data set across (T1c-T2)
pair-wise stage.
Transcript ID Chr Description Gene
NM 000110 1 Homo sapiens dihydropyrimidine
dehydrogenase transcript variant 1
DPYD
NM 000710 14 Homo sapiens Bradykinin receptor B1 BDKRB1
NM 001042574 15 Homo sapiens CREB regulated
transcription coactivator 3 transcript
variant 2
CRTC3
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Table B.1.2: Details about selected protein isoforms from Long’s data set across (T2-T2a)
pair-wise stage.
Transcript ID Chr Description Gene
NM 001146192 1 Homo sapiens syntaxin 4, transcript
variant 1
ZMYND12
NM 001272095 16 Homo sapiens Bradykinin receptor B1 STX4
NM 003540 6 Homo sapiens histone cluster 1 H4
family member f
HIST1H4F
NM 004860 17 Homo sapiens FMR1 autosomal
homolog 2
FXR2
NM 032850 15 Homo sapiens zinc finger FYVE-type
containing 19, transcript variant 3
ZFYVE19
NM 145892 16 Homo sapiens RNA binding protein,
fox-1 homolog 1, transcript variant 2
RBFOX1
NM 153274 1 Homo sapiens RNA binding protein,
fox-1 homolog 1, transcript variant 2
BEST4
NM 172350 1 Homo sapiens CD46 molecule, transcript
variant n
CD46
Table B.1.3: Details about selected protein isoforms from Long’s data set across (T2a-T2b)
pair-wise stage.
Transcript ID Chr Description Gene
NM 000681 10 Homo sapiens adrenoceptor alpha 2A ADRA2A
NM 001134473 16 Homo sapiens Gse1 coiled-coil protein,
transcript variant 2
GSE1
NM 001145138 11 Homo sapiens RELA proto-oncogene,
NF-kB subunit, transcript variant 2
RELA
NM 007225 17 Homo sapiens neurexophilin 3 NXPH3
NM 032023 10 Homo sapiens Ras association domain
family member 4
RASSF4
Table B.1.4: Details about selected protein isoforms from Long’s data set across (T2b-T2c)
pair-wise stage.
Transcript ID Chr Description Gene
NM 000029 1 Homo sapiens angiotensinogen AGT
NM 001711 X Homo sapiens Biglycan BGN
NM 032023 10 Homo sapiens Ras association domain
family member 4
RASSF4
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Table B.1.5: Details about selected protein isoforms from Long’s data set across (T2c-T3a)
pair-wise stage.
Transcript ID Chr Description Gene
NM 001198979 1 Homo sapiens small ArfGAP2, transcript
variant 2
SMAP2
NM 003546 6 Homo sapiens histone cluster 1 H4
family member l
HIST1H4L
NM 032875 17 Homo sapiens F-box and leucine rich
repeat protein 20, transcript variant 1
FBXL20
Table B.1.6: Details about selected protein isoforms from Long’s data set across (T2c-T3a)
pair-wise stage.
Transcript ID Chr Description Gene
NM 002154 5 Homo sapiens heat shock protein family
A (Hsp70) member 4
HSPA4
NM 006465 15 Homo sapiens AT-rich interaction
domain 3B , transcript variant 2
ARID3B
NM 024604 12 Homo sapiens RNA polymerase II
associated protein 3, transcript variant 1
RPAP3
NM 182485 4 Homo sapiens cytoplasmic
polyadenylation element binding protein
2, transcript variant B
CPEB2
70
Table B.1.7: Details about selected protein isoforms from Long’s data set across (T2c-T34)
pair-wise stage.
Transcript ID Chr Description Gene
NM 001024674 14 lin-52 DREAM MuvB core complex
component
ADRA2A
NM 001023567 15 golgin A8 family, member B, transcript
variant 1
GOLGA8B
NM 001099285 2 Prothymosin, alpha, transcript variant 1 PTMA
NM 001198979 1 small ArfGAP2, transcript variant 2 SMAP2
NM 001256 17 cell division cycle 27, transcript variant 2 CDC27
NM 002437 2 MPV17, mitochondrial inner membrane
protein
MPV17
NM 003387 2 WAS/WASL interacting protein family
member 1, transcript variant 1
WIPF1
NM 001257413 17 IKAROS family zinc finger 3, transcript
variant 12
IKZF3
NM 006214 10 phytanoyl-CoA 2-hydroxylase ,
transcript variant 1
PHYH
NM 016940 21 RWD domain containing 2B , transcript
variant 1
RWDD2B
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